Biosergen’s Q3 report, released today, outlines steady progress in the development of BSG005, the company’s broad-spectrum antifungal candidate aimed at severe and treatment-resistant infections. Preparations for the next patient cohort, upgrades to GMP manufacturing and ongoing regulatory work in the United States indicate a programme moving methodically toward its upcoming milestones. BioStock reached out to CEO Tine Olesen for a comment.
Read the full interview at biostock.se:
Biosergen comments on continued progress in the third quarter
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/